Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
ProMIS Neurosciences Inc
PMN
Healthcare
Biotechnology
ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine...
applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:PMN)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(107)
•••
M101
X
View Profile
View Bullboard History
Comment by
M101
on Feb 27, 2024 4:39pm
RE:RE:infomercial
If the market really turns south this year, as I believe it will, then we'll be somewhat relieved that the Boston Group is in for the long term and can absorb any remaining weak hands. I have no
...more
(13)
•••
garygp
X
View Profile
View Bullboard History
Comment by
garygp
on Feb 27, 2024 2:50pm
RE:infomercial
M101 You could use any one of your above noted chapters and write a compelling story on the abuse shareholders have taken at the hands of all BOD members over the past 20 years. But, what the he!!.&
...more
Silvercorp to Acquire Adventus, Creating a Diversified Mining Company
posted May 02, 2024 9:00am by
Adventus Mining Corp.
-
|
Under the terms of the Arrangement Agreement, each holder of the common shares of Adventus will receive 0.1015 of one Silvercorp common share in exchange for each Adventus Share at the effective time of the Transaction. The Exchange Ratio implies consideration of C$0.50 per Adventus Share ...read more
(107)
•••
M101
X
View Profile
View Bullboard History
Post by
M101
on Feb 26, 2024 4:38pm
infomercial
I guess when you're paid to write propaganda you slip in the occasional lame joke just for sanity. "Elan’s vaccination study, in particular, created numerous headaches for DeMattos. The
...more
(107)
•••
M101
X
View Profile
View Bullboard History
Comment by
M101
on Feb 23, 2024 1:34pm
RE:Another side show
I don't see a problem with this if what they want is minority position long term investors while not wasting resources on shorter term traders. The website already posts far more relevant
...more
(44)
•••
FarmerBetsy
X
View Profile
View Bullboard History
Post by
FarmerBetsy
on Feb 22, 2024 10:11pm
Another side show
PR for more information or to schedule a meeting, please visit the conference page or contact Promis Neurosciences Investor Relations..Should upgrade Promis website company info under
...more
(107)
•••
M101
X
View Profile
View Bullboard History
Comment by
M101
on Feb 22, 2024 2:46pm
RE:RE:RE:what gives?
Good press release, "Promis will present at ... ". Present at instead of present what, that's all anyone really needed to know at this pure risk mitigation phase.
(66)
•••
retiredcop
X
View Profile
View Bullboard History
Comment by
retiredcop
on Feb 22, 2024 10:33am
RE:RE:what gives?
The presentation will probabaly be the usual info provided to in. They would get way more traction if they make any revelations on the clinical results as a company press release or in
...more
(38)
•••
BottomBroker
X
View Profile
View Bullboard History
Comment by
BottomBroker
on Feb 22, 2024 8:58am
RE:what gives?
Dare I say it, but maybe they'll report postive data from Phase 1a trials at this conference next week?
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Feb 22, 2024 7:00am
New Press Release - ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Feb. 22, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced that Neil...
read article.
(82)
•••
Gbathat
X
View Profile
View Bullboard History
Post by
Gbathat
on Feb 21, 2024 6:10pm
what gives?
interesting rise on low volume today...
(107)
•••
M101
X
View Profile
View Bullboard History
Comment by
M101
on Feb 15, 2024 5:37pm
RE:probably nothing
Speaking of nothing, we're now beyond the 85 day 1a study period of the Nov 20 news release.
(82)
•••
Gbathat
X
View Profile
View Bullboard History
Post by
Gbathat
on Feb 15, 2024 3:47pm
probably nothing
but when I google search pmn310 and restrict results to sites updated in the last week, I get a link to the AAIC 2024 conference, with said link being updated 7 days ago. I see no mention of PMN310
...more
(107)
•••
M101
X
View Profile
View Bullboard History
Comment by
M101
on Feb 13, 2024 4:44pm
RE:Far out question for the experts here
A few years ago I would have thought that was too corrupt even for the FDA, which is why I thought Goldstein was needlessly pandering. Not any more, after Covid there is no reason to believe the US
...more
(3)
•••
letsgo111
X
View Profile
View Bullboard History
Post by
letsgo111
on Feb 13, 2024 3:04am
Far out question for the experts here
So safe to say PMN is struggling with making progress getting FDA approval. Not a knock against them, they could have an game changing product. But is this the only way forward? If it is
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Mullen Group Ltd. Reports 2024 First Quarter Financial Results
Significant New Silver Discoveries in the Famous Keno Hill District in the Yukon
This Gambling Tech Stock is Future-Proofing the World’s Casinos and has No Direct Competition
Silvercorp to Acquire Adventus, Creating a Geographically Diversified Mining Company
Revolutionary Tech Company Announces Fourth Quarter and Full Year 2023 Results
Drill Permit Approval Received for New Mexico Lithium Project
This profitable gold stock is on its way up